GGrantIndex
← Leaderboards

Michael H Weisman

University Of California San Diego

$0
Attributed
$0
Total exposure
5
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding mix

By agency

NIH$0 · 5

By mechanism

M01$0 · 5

Top collaborators

No co-investigators on record.

Most similar at University Of California San Diego

Same institution · by research overlap

Others in their field

Top investigators on “Human Subject

Research focus

Human SubjectClinical ResearchDrug Screening /EvaluationHuman Therapy EvaluationSign /SymptomJoint DisorderCombination ChemotherapyRheumatoid ArthritisMethotrexateAntiantibodyDosagePharmacokineticsQuality Of LifeSkeletal Disorder ChemotherapyOsteoarthritisPathologic ProcessPlacebosRemission /RegressionTumor Necrosis Factor AlphaAcute Disease /DisorderAntirheumatic AgentsChimeric ProteinsChloroquineCorticosteroids

Grant awards (45)

HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2002 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2002 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2002 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2002 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2002 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2001 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2001 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2001 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
LEFLUNOMIDE VS PLACEBO FOR ACTIVE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2000 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2000 · RR
HYDROXYCHLOROQUINE OR ACETAMINOPHEN IN NODAL ARTHRITIS$0
M01 · FY2000 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
RO32 3555 TROCADE IN STRUCTURAL JOINT DAMAGE IN RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
ANTI TNF CHIMERIC MONOCLONAL ANTIBODY IN ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR
LJP 394 ADMINISTERED TO PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR